Unknown

Dataset Information

0

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.


ABSTRACT: Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor-binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.

SUBMITTER: Weisblum Y 

PROVIDER: S-EPMC7723407 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8341613 | biostudies-literature
| S-EPMC7737530 | biostudies-literature
| S-BSST379 | biostudies-other
| S-EPMC7980144 | biostudies-literature
| S-EPMC8167834 | biostudies-literature
| S-EPMC7945862 | biostudies-literature
| S-EPMC8502962 | biostudies-literature
| S-EPMC8213968 | biostudies-literature